Arterioscope, the innovative med-tech startup spun out from Graz University of Technology in Austria, has recently raised 600,000 euros in funding as it forges ahead in transforming cardiovascular health diagnostics. With its focus on AI-powered medical diagnostics, Arterioscope is building a groundbreaking platform for non-invasive biomarker detection, targeting critical indicators such as BNP, Troponin, and ApoB. The new capital injection will be dedicated to enhancing and scaling the company’s patented AI-algorithm, which interprets measurement data from common devices like ECG (Electrocardiography) and PPG (Photoplethysmography) in real-time. This approach allows for the conversion of routine data into patient-specific models that ultimately support optimal and cost-efficient treatment strategies.
This funding milestone marks a significant step forward for Arterioscope as it continuously works to revolutionize the field of cardiovascular diagnostics. The investment not only reinforces confidence in Arterioscope’s innovative technology and vision but also provides the resources needed to further research and development initiatives. The company is set to expand its technical capabilities, refine its algorithms, and explore new partnerships and market opportunities, all while maintaining its mission of delivering accessible and reliable health insights on a global scale. As cardiovascular diseases remain a leading cause of morbidity and mortality, the timely integration of advanced AI with non-invasive diagnostic tools offers an exciting prospect for doctors and patients alike. Join Arterioscope on this transformative journey as they push the boundaries of traditional healthcare diagnostics and pioneer a more precise, personalized approach to cardiovascular care.
